Harnessing the power of KISIMA® immunisation technology to discover and develop therapeutic vaccines

A novel approach to therapeutic vaccines

AMAL aims to tackle the obstacles for effective anti-cancer therapy by stimulating a patient’s immune system in a unique way.

More about AMAL

First-in-class immunisation technology

KISIMA®, our unique proprietary protein-based immunisation platform is self-adjuvanting and delivers several antigens in one single vaccine.

More about KISIMA®

Transforming the prospects of cancer patients

We focus on the development of viable effective cancer therapies. Our most advanced asset is ATP128, a therapeutic vaccine for the treatment of metastatic colorectal cancers.

More about portfolio

Latest

News

More news

Events

  • Personalized Cancer Vaccine Summit 2024

    December 3-5, Boston, United States
    Marie-Laure Santiago-Raber, Chief Scientific Officer, and Laetitia Devy-Dimanche, Chief Executive Officer, attending

  • CICON 2024

    Sept 8-11, 2024, Washington DC, United States
    Elodie Belnoue, Senior Director Translational Research, presenting (poster)

  • Immunology day 2024 - Geneva State

    June 20, 2024, Geneva, Switzerland
    Erika Riva, Scientist, presenting

More events

You are now leaving our website

Using this link will let you leave a website of Amal Therapeutics or to a different domain under the control of Amal Therapeutics. In the event that the linked site is not under the control of Amal Therapeutics but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, Amal Therapeutics shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites.

This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by Amal Therapeutics of the site.

Target URL:

OK